Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Bristol-Myers Squibb Partner on Companion Dx Development for Immunotherapy

NEW YORK (GenomeWeb) – Illumina and Bristol-Myers Squibb announced after the close of the market Friday that they will collaborate on developing and commercializing companion diagnostics to support BMS' oncology drug pipeline.

The companies plan to develop a diagnostic version of Illumina's TruSight Oncology 500, an assay being developed to target most of the known biomarkers for cancer drugs, including tumor mutation burden and miscrosatellite instability. The panel will run on Illumina's NextSeq 550Dx.

"Through our deep understanding of cancer biology and emerging research, we recognize the importance for physicians to know each patient's biomarker status to help fight their cancer in a more personalized way," Saurabh Saha, senior vice president, global head of translational medicine at Bristol-Myers Squibb, said in a statement. "We are excited to partner with Illumina to pursue development of diagnostics that can help predict which patients will have the potential to benefit most from our immunotherapies."

Earlier this week, Illumina announced a separate partnership with Loxo Oncology to develop a pan-cancer companion diagnostic with a different assay, the TruSight 170 panel. 

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.